SLC5A2 and type 2 diabetes mellitus: Within the framework of contemporary clinical guidelines, which already recommend SGLT2 inhibitors as cornerstone therapy for patients with type 2 diabetes and heart failure, our findings provide important mechanistic reinforcement [24].